Avoid Clinical Trial Enrollment Pitfalls

May 6, 2018

Selecting the right site is the single most crucial decision
you’ll make about your next clinical trial. And perhaps the
single most important consideration in selecting a site is
whether it can make its enrollment. Many don’t; in fact,
20-25 percent of all clinical studies close because they
fail to meet enrollment targets.

Spotlight

Nobel Ilac A.S

Nobel İlaç has been active in the international market with a national capital from 1964 until today and develops pioneer and novelist products which increases the life quality by using the resources productively with the principle of being a worldwide trustworthy organization.

OTHER WHITEPAPERS
news image

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

Read More
news image

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Read More

Spotlight

Nobel Ilac A.S

Nobel İlaç has been active in the international market with a national capital from 1964 until today and develops pioneer and novelist products which increases the life quality by using the resources productively with the principle of being a worldwide trustworthy organization.

Events